Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

Inclusion Criteria: * Age 18 years or older * Documented HIV-1 seropositive * Not on HIV-1 antiretroviral therapy nor planning to initiate antiretroviral therapy during the study period * Detectable HIV-1 plasma viral load * HSV-2 seropositive as determined by western blot * Not intending to move out of the area for the duration of study participation * Willing and able to provide independent written informed consent * Willing and able to undergo clinical evaluations * Willing and able to take study drug as directed * Willing and able to adhere to follow-up schedule Exclusion Criteria: * Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir * Planned open label use of acyclovir, valacyclovir, or famciclovir * History of evidence of CMV disease * Known medical history of seizures * Known renal insufficiency, defined as serum creatinine greater than 1.5 mg/dl * AST or ALT greater than 3 times upper limit of normal * Hematocrit less than 30 % * Neutropenia, defined as absolute neutrophil count less than 1000 * Thrombocytopenia, defined as platelet count less than 75,000 * History of thrombotic microangiopathy * For women, pregnancy as confirmed by a urine pregnancy test * Any other condition which, in the opinion of the principal investigator, may compromise the ability to follow study procedures and complete the study